Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The current therapeutic strategy for disseminated intravascular coagulation (DIC) is limited to control of the underlying disease, and methods for the effective management of DIC have not been established. We report the successful use of tranexamic acid (TA) combined with unfractionated heparin in a patient with life-threatening bleeding from the sigmoid colon caused by DIC. A 35-year-old man who had undergone allogeneic bone marrow transplantation for chronic myelogenous leukemia was referred for relapse of his leukemia. The patient was first treated with imatinib at 600 mg/day. Although the disappearance of leukemic cells and a decrease in the BCR/ABL fusion gene were observed, he developed massive bleeding from the sigmoid colon after defecation. A laboratory diagnosis of DIC with prominent fibrinolysis was based on elevated levels of both plasmin-α2-plasmin inhibitor complex and thrombin-antithrombin III complex. Despite vigorous supportive therapy, including multiple transfusions and aggressive fluid resuscitation, the patient developed hypovolemic shock due to the uncontrollable bleeding. TA combined with unfractionated heparin was instituted to inhibit excessive fibrinolysis. A prompt response was observed soon after the commencement of therapy. No organ dysfunction was observed throughout TA and heparin use. To our knowledge, this report is the first to describe successful treatment with TA combined with heparin for life-threatening intestinal bleeding due to acute DIC associated with hematologic malignancy.
- Levi M, Cate HT. Disseminated intravascular coagulation.N Engl J Med. 1999;341:586–592. CrossRef
- Tallman MS, Kwaan HC. Reassessing the hematostatic disorder associated with acute promyelocytic leukemia.Blood. 1992;79:543–553.
- Levi M. Current understanding of disseminated intravascular coagulation.Br J Haematol. 2004;124:567–576. CrossRef
- Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia.Semin Thromb Hemost. 2001;27:593–604. CrossRef
- Hanna BD, Bernstein M, Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants.Am J Pediatr Hematol Oncol. 1989;11:191–195.
- Takada A, Takada Y, Mori T, Sakaguchi S. Prevention of severe bleeding by tranexamic acid in a patient with disseminated intravascular coagulation.Thromb Res. 1990;58:101–108. CrossRef
- Wada H, Kumeda Y, Ogasawara Z, et al. Plasminogen activators and their inhibitors in leukemic cell homogenates.Am J Hematol. 1993;42:166–170. CrossRef
- Robbie L, Berry S, Moir E, et al. Myeloid leukemic cells can lyse fibrin directly.Br J Haematol. 2000;111:524–529. CrossRef
- Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Leu EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia.N Engl J Med. 1999;340:994–1004. CrossRef
- Asakura H, Jokaji H, Saito M, et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers.Blood Coagul Fibrinolysis. 1994;5:829–832. CrossRef
- Asakura H, Sano Y, Yamazaki M, Morishita E, Miyamoto K, Nakao S. Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats: an effect of tranexamic acid.Haematologica. 2004;89:757–758.
- Avvisati G, ten Cate JW, Büller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukemia.Lancet. 1989;2:122–124. CrossRef
- Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early death and anti-hemorrhagic treatments in acute promyelocytic leukemia: A GIMEMA retrospective study in 268 consecutive patients.Blood. 1990;75:2112–2117.
- Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group.Blood. 2004;103:1237–1243. CrossRef
- Hashimoto S, Koike T, Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans-retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage.Leukemia. 1994;8:1113–1115.
- Ontachi Y, Asakura H, Arahata M, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm.Circ J. 2005;69:1150–1153. CrossRef
- Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S. Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid.Haematologica. 2005;90(Suppl):ECR29.
- Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation: assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.Haemostasis. 1992;22:179–186.
- Okajima K, Kohno I, Soe G, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency.Am J Hematol. 1994;45:16–24. CrossRef
- Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis
International Journal of Hematology
Volume 86, Issue 5 , pp 403-406
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Disseminated intravascular coagulation (DIC)
- Tranexamic acid (TA)
- Unfractionated heparin
- Plasmin-α2-plasmin inhibitor complex (PIC)
- Thrombin-antithrombin III complex (TAT)
- Chronic myelogenous leukemia (CML)
- Industry Sectors
- Author Affiliations
- 1. Division of Hematology/Oncology, Department of Medicine, Kameda General Hospital, 929 Higashi-Chou, 296-8602, Kamogawa-shi, Chiba, Japan
- 2. Department of Internal Medicine III, Kanazawa University School of Medicine, Ishikawa, Japan